Sunil Healthcare Limited reported a standalone net loss of Rs 5.30 crore for FY26, largely driven by a Rs 9.59 crore exceptional expense involving provisions for its Mexican subsidiary and assets written off after a fire at its Alwar plant. Despite this, the company achieved a consolidated profit of Rs 4.01 crore. CARE Ratings has downgraded the company's long-term and short-term bank facilities due to the challenging fiscal performance. The company has opted not to pay a dividend to preserve cash for growth.
Sunil Healthcare Reports FY26 Financials Amid Exceptional Charges
Standalone Net Loss: Rs 5.30 crore; Consolidated Profit: Rs 4.01 crore.
Reader Takeaway: Exceptional provisions and fire-related asset write-offs hurt standalone bottom line, though consolidated operations turned profitable.
What just happened
Sunil Healthcare released its annual financial results for the year ended March 31, 2026. The company posted a standalone net loss of Rs 5.30 crore, a stark reversal from the profit of Rs 0.21 crore recorded in the previous fiscal year. This performance was heavily impacted by exceptional items totaling Rs 9.59 crore. Conversely, the company’s consolidated performance showed resilience with a profit after tax of Rs 4.01 crore, improving upon the loss of Rs 1.42 crore seen in FY 2024-25.
Why this matters
The divergence between standalone and consolidated results highlights the impact of specific corporate restructuring and operational events. The company made a significant provision of Rs 9.47 crore regarding the recoverability of balances from its subsidiary, Sunil Healthcare Mexico SA DE CV. Additionally, a fire at the Alwar manufacturing plant resulted in the write-off of assets valued at Rs 3.56 crore, though the firm anticipates an insurance recovery of Rs 3.44 crore.
Risks to watch
CARE Ratings has downgraded the company’s credit profile. Long-term bank facilities have been revised to CARE BB+ with a Stable outlook, while short-term facilities are now rated CARE A4+. Investors should monitor the status of the ongoing insurance claim related to the Alwar plant and the recovery progress regarding the Mexican subsidiary, as these factors remain critical to balance sheet stability.
Operations and shareholder updates
Sunil Healthcare maintains an annual production capacity of 15 billion capsules. The Board of Directors has decided against declaring a dividend for the year to support internal accruals. The 52nd Annual General Meeting is scheduled for September 28, 2026, via video conferencing. Shareholders should note that the register of members will be closed from September 22 to September 28, 2026, for this purpose.